MEDICO REMEDIES LIMITED
Latest filings
- Medico Remedies clarifies on stock price movement query · Compliance
- BSE asks Medico Remedies for clarification on sharp price move · Regulatory & Legal
- Trading window closed from Oct 1, 2026 until Q2 results are declared · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical formulations, with exports accounting for the bulk of sales. In Q4 FY26, exports were Rs 5,364 lakhs against domestic sales of just Rs 274 lakhs, and in Q3 FY26 the split was Rs 5,156 lakhs exports versus Rs 690 lakhs domestic, indicating a heavily export-oriented business. FY26 revenue from operations was Rs 206.38 crore, up 36.85% year-on-year, with net profit of Rs 13.12 crore. The cost stack is dominated by materials at 72% of revenue, while employees account for 3.6%, other opex 14.8%, and depreciation 1.5%, leaving an EBITDA margin of around 11.13%. Working capital has expanded with growth: trade receivables rose to Rs 8,199 lakhs and inventories to Rs 3,002 lakhs by FY26 year-end. Capex was reported at 0% of revenue in FY26. Bank facilities of Rs 42 crore are in place with Kotak Mahindra Bank (Rs 19 crore term loan, Rs 18 crore packing credit, Rs 5 crore letter of credit), and the company holds a CRISIL BBB-/Stable long-term rating. The company periodically files disclosures about receiving new orders or contracts, though values, clients and geographies are not specified in the filings.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from MEDICO REMEDIES LIMITED's filed financials and exchange disclosures
What does MEDICO REMEDIES LIMITED do?
MEDICO REMEDIES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol MEDICO.
Is MEDICO REMEDIES LIMITED profitable?
Yes. Over the trailing twelve months MEDICO REMEDIES LIMITED reported a net profit of ₹14 Cr on revenue of ₹238 Cr.
Does MEDICO REMEDIES LIMITED pay a dividend?
Not in the latest reported year — MEDICO REMEDIES LIMITED's dividend payout for FY26 was nil.
Is MEDICO REMEDIES LIMITED debt-free?
No. It reported borrowings of ₹19 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹17 Cr after cash. Debt stands at 0.25× equity. That is higher than 62% of its 166 Pharmaceuticals peers.
Is MEDICO REMEDIES LIMITED expensive compared with its peers?
On trailing P/E, MEDICO REMEDIES LIMITED ranks 28 of 158 in Pharmaceuticals — cheaper than 82% of them, against an industry median of 32.0×. This is a position, not a valuation judgement.
How much does the MEDICO REMEDIES LIMITED share price move in a day?
On a typical session MEDICO REMEDIES LIMITED moves 1.40% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track MEDICO REMEDIES LIMITED's announcements?
Every NSE and BSE filing by MEDICO REMEDIES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.